Abstract:Introduction: Novel compounds targeting various aspects of fibrogenesis have been developed consequent to the increasing knowledge of the pathogenetic mechanisms of the interstitial lung diseases (ILDs). The authors review the evolution of treatment approaches in the ILDs, informed by recent placebo-controlled trials, and discuss current clinical trials in which emerging pathogenetic mechanisms are targeted as novel therapeutic agents. Areas covered: In idiopathic pulmonary fibrosis (IPF), recent randomised, placebo-controlled trials have tested the efficacy of new therapies, and although primary end points have not been met in most, treatment effects have been observed. The demonstration of harmful effects from widely used IPF therapies has been equally important. Pirfenidone and nintedanib are emerging agents that exert pleiotropic effects, reflective of the multiple mechanistic pathways of IPF. Treatment may necessitate a similarly multifaceted approach using combination regimens of antifibrotic and antioxidant agents in order to be effective. In other ILDs, including systemic sclerosis, other connective tissue diseases and pulmonary sarcoidosis, the inflammatory/fibrotic model remains appropriate. Studies in systemic sclerosis have provided 'proof of concept' data for immunosuppressive therapy in the prevention of disease progression but there is a continuing need for controlled clinical trials in the more prevalent ILDs. Expert opinion: In IPF, significant treatment effects have been reported with pirfenidone, nintedanib and N-acetylcysteine. Combinations of these pleiotropic agents, along with future monotherapies, in 'oncological regimens' may hold the key to more effective IPF treatment. In disorders other than IPF, there is an ongoing need for the controlled evaluation of traditional anti-inflammatory and immunosuppressive therapies. 'Cohort enrichment' (the selective recruitment of patients most likely to progress) holds the key to the identification of worthwhile treatment benefits.

Emerging Opportunities to Treat Idiopathic Pulmonary Fibrosis: Design, Discovery, and Optimizations of Small-Molecule Drugs Targeting Fibrogenic Pathways.

Idiopathic Pulmonary Fibrosis: 8 Years On After Nintedanib and Pirfenidone Approval—What Is on the Horizon?

Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis

Progress in understanding and treating idiopathic pulmonary fibrosis: recent insights and emerging therapies

Current and novel drug therapies for idiopathic pulmonary fibrosis

Novel drug targets for idiopathic pulmonary fibrosis

Perspectives of PDE Inhibitor on Treating Idiopathic Pulmonary Fibrosis

Advances of Targets and Therapeutic Drugs for Idiopathic Pulmonary Fibrosis

Novel therapeutic strategies and drugs for idiopathic pulmonary fibrosis

Updates in pharmacotherapy for idiopathic pulmonary fibrosis

Exploring therapeutic targets for molecular therapy of idiopathic pulmonary fibrosis

Targeting the PI3K/mTOR pathway in idiopathic pulmonary fibrosis: Advances and therapeutic potential

The evolving pharmacotherapy of pulmonary fibrosis

Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis

Comprehensive review of potential drugs with anti-pulmonary fibrosis properties

Pulmonary fibrosis: Emerging diagnostic and therapeutic strategies

Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF)

Inhibitor of PD-1/PD-L1: a new approach may be beneficial for the treatment of idiopathic pulmonary fibrosis

Recent evidence for pharmacological treatment of idiopathic pulmonary fibrosis

Targeting PI3K/AKT Signaling for Treatment of Idiopathic Pulmonary Fibrosis

Evidence from recent clinical trials in fibrotic interstitial lung diseases